Multi-Year Summary

Key figures from recent years.

MSEK
Net sales
2023/2024
484,80
2022/2023 (12 months)
432,90
2022/2023 (16 months)
540,10
2021
385.50
2020
406.60
MSEK
Gross profit
2023/2024
240,50
2022/2023 (12 months)
174,40
2022/2023 (16 months)
209,50
2021
176.30
2020
202.00
MSEK
Gross margin
2023/2024
49,6%
2022/2023 (12 months)
40,3%
2022/2023 (16 months)
38,8%
2021
45,7%
2020
49,7%
MSEK
EBITDA
2023/2024
47,50
2022/2023 (12 months)
-12,90
2022/2023 (16 months)
-27,50
2021
17.60
2020
63.50
MSEK
Profit (loss) before tax
2023/2024
32,60
2022/2023 (12 months)
-62,60
2022/2023 (16 months)
-90,20
2021
-19.00
2020
-28.20
MSEK
Cash flow from operating activities
2023/2024
-104,70
2022/2023 (12 months)
-17,60
2022/2023 (16 months)
-12,90
2021
54.30
2020
37.20
MSEK
Cash flow from investing activities
2023/2024
-19,6
2022/2023 (12 months)
-12,20
2022/2023 (16 months)
-16,60
2021
-9.50
2020
-20.30
MSEK
Earnings per share, SEK
2023/2024
0,22
2022/2023 (12 months)
-0,61
2022/2023 (16 months)
-0,87
2021
-0.19
2020
0.24
MSEK
Equity per share, SEK
2023/2024
0,42
2022/2023 (12 months)
-0,61
2022/2023 (16 months)
-0,39
2021
0.39
2020
0.58
MSEK
Equity ratio
2023/2024
7,6%
2022/2023 (12 months)
-12,1%
2022/2023 (16 months)
-12,1%
2021
7.40%
2020
12.4%
MSEK
Number of employees at the end of period
2023/2024
126
2022/2023 (12 months)
131
2022/2023 (16 months)
131
2021
122
2020
118

Interested in what is happening at Bluefish? Sign up and stay up to date.

Cookies

This site uses cookiesfor statistics and user experience.

Bluefish Pharmaceuticals uses cookies to improve your user experience, provide insights for the improvement and further development of the website, and to deliver more relevant offers to you.

Please read our privacy policy. If you agree to our use, choose Allow All. If you want to change your choice later, you can find this option at the bottom of the page.